NCYT — Novacyt SA Share Price
Last trade - 00:00- £29.57m
- £9.76m
- £11.58m
- 39
- 44
- 26
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.42 | ||
| Price to Tang. Book | 0.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.59 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.55% | ||
| Return on Equity | -42.04% | ||
| Operating Margin | -205.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 11.47 | 277.2 | 92.6 | 21.04 | 11.58 | n/a | n/a | -0.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. It provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. It offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. It creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.
Directors
- James Wakefield NEC
- David Allmond CEO (51)
- James McCarthy CFO
- Trevor Reginald CTO
- Anthony Dyer EDR
- Mandy Cowling DIR
- Paul Eros EXB
- Steve Gibson EXB
- Lisa Henriet EXB
- Navin Nauth-Misir EXB
- Guillermo Raimondo EXB
- Jean-Pierre Crinelli NED (70)
- Andrew Heath NID
- Edwin Snape NID (81)
- Juliet Thompson NID
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- July 3rd, 2006
- Public Since
- October 12th, 2012
- No. of Employees
- 240
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 70,564,636
- Address
- 131 Boulevard Carnot, Le Vesinet, VELIZY VILLACOUBLAY, 78110
- Web
- https://novacyt.com/fr
- Phone
- +33 139465104
- Auditors
- Deloitte & Associes
Latest News for NCYT
Upcoming Events for NCYT
Full Year 2024 Novacyt SA Earnings Release
Novacyt SA Annual Shareholders Meeting
Half Year 2025 Novacyt SA Earnings Release
Similar to NCYT
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 22:21 UTC, shares in Novacyt SA are trading at 41.05p. This share price information is delayed by 15 minutes.
Shares in Novacyt SA last closed at 41.05p and the price had moved by -32.7% over the past 365 days. In terms of relative price strength the Novacyt SA share price has underperformed the FTSE All Share Index by -35.35% over the past year.
The overall consensus recommendation for Novacyt SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNovacyt SA does not currently pay a dividend.
Novacyt SA does not currently pay a dividend.
Novacyt SA does not currently pay a dividend.
To buy shares in Novacyt SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 41.05p, shares in Novacyt SA had a market capitalisation of £29.57m.
Here are the trading details for Novacyt SA:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: NCYT
Based on an overall assessment of its quality, value and momentum Novacyt SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Novacyt SA is 24,358.62p. That is 59238.9% above the last closing price of 41.05p.
Analysts covering Novacyt SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novacyt SA. Over the past six months, its share price has underperformed the FTSE All Share Index by -25.12%.
As of the last closing price of 41.05p, shares in Novacyt SA were trading -25.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novacyt SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 41.05p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Novacyt SA's management team is headed by:
- James Wakefield - NEC
- David Allmond - CEO
- James McCarthy - CFO
- Trevor Reginald - CTO
- Anthony Dyer - EDR
- Mandy Cowling - DIR
- Paul Eros - EXB
- Steve Gibson - EXB
- Lisa Henriet - EXB
- Navin Nauth-Misir - EXB
- Guillermo Raimondo - EXB
- Jean-Pierre Crinelli - NED
- Andrew Heath - NID
- Edwin Snape - NID
- Juliet Thompson - NID